TY - JOUR
T1 - Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis
AU - Kohno, S.
AU - Koga, H.
AU - Kaku, M.
AU - Maesaki, S.
AU - Hara, K.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1992
Y1 - 1992
N2 - The efficacy of ofloxacin, rifampicin and isoniazid was prospectively compared with the regimen of ethambutol, rifampicin and isoniazid for the primary treatment of pulmonary tuberculosis in 124 patients. All drugs were given orally daily for nine months. Culture conversion rates three months after starting treatment were 98 percent in the ofloxacin group and 94 percent in the ethambutol group; by six months all patients in both groups were culture-negative. Significant radiological improvement of pulmonary infiltrates was observed in 83 percent of the ofloxacin group and 85 percent of the ethambutol group one year after starting treatment. No relapse in either group was observed during a two-year follow-up period after the cessation of chemotherapy. Ofloxacin appears to be as useful as ethambutol in the treatment of pulmonary tuberculosis when either drug is combined with isoniazid and rifampicin.
AB - The efficacy of ofloxacin, rifampicin and isoniazid was prospectively compared with the regimen of ethambutol, rifampicin and isoniazid for the primary treatment of pulmonary tuberculosis in 124 patients. All drugs were given orally daily for nine months. Culture conversion rates three months after starting treatment were 98 percent in the ofloxacin group and 94 percent in the ethambutol group; by six months all patients in both groups were culture-negative. Significant radiological improvement of pulmonary infiltrates was observed in 83 percent of the ofloxacin group and 85 percent of the ethambutol group one year after starting treatment. No relapse in either group was observed during a two-year follow-up period after the cessation of chemotherapy. Ofloxacin appears to be as useful as ethambutol in the treatment of pulmonary tuberculosis when either drug is combined with isoniazid and rifampicin.
UR - http://www.scopus.com/inward/record.url?scp=0026621642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026621642&partnerID=8YFLogxK
U2 - 10.1378/chest.102.6.1815
DO - 10.1378/chest.102.6.1815
M3 - Article
C2 - 1446494
AN - SCOPUS:0026621642
VL - 102
SP - 1815
EP - 1818
JO - Diseases of the chest
JF - Diseases of the chest
SN - 0012-3692
IS - 6
ER -